Overview
Superluminal Medicines is a company headquartered in United States.
Summary generated from the structured facts on this page.
Funding
Amounts as reported; USD estimates shown only when they matchListed 2 funding records. Latest funding: $60M (Series B), Sep 3, 2026.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Sep 3, 2026 | $60M · Series B | BVF Partners, Catalio Capital Management, Cooley, Deep Track Capital, Eli Lilly, Gaingels, Insight Partners, NVIDIA, Perceptive Advisors, RA Capital Management | No source link |
Evidence Superluminal Medicines raises USD 60 million in Series B financingOn 2026-09-03, according to Xiniu Data, Superluminal Medicines completed Series B financing, raising USD 60 million. Investors were lead investor BVF Partners, RA Capital Management, Perceptive Advisors, NVIDIA and others. The company is a provider of U.S. AI generation drugs services. Translated source brief, not a quotation. Check the original before citing. Sources · 0
BVF Partners, Catalio Capital Management, Cooley, Deep Track Capital, Eli Lilly, Gaingels, Insight Partners, NVIDIA, Perceptive Advisors, RA Capital Management | |||
| Sep 9, 2024 | $120M · Series A | Catalio Capital Management, Cooley, Eli Lilly, Eli Lilly and Company, Gaingels, Insight Partners, NVIDIA, RA Capital Management | No source link |
Evidence No source brief is attached to this record. Sources · 0
Catalio Capital Management, Cooley, Eli Lilly, Eli Lilly and Company, Gaingels, Insight Partners, NVIDIA, RA Capital Management | |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 2 valuation records.
No chartable valuation estimates yet.
2 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Sep 3, 2026 | — · Series B | BVF Partners, Catalio Capital Management, Cooley, Deep Track Capital, Eli Lilly, Gaingels, Insight Partners, NVIDIA, Perceptive Advisors, RA Capital Management | No source link |
Evidence Superluminal Medicines raises USD 60 million in Series B financingOn 2026-09-03, according to Xiniu Data, Superluminal Medicines completed Series B financing, raising USD 60 million. Investors were lead investor BVF Partners, RA Capital Management, Perceptive Advisors, NVIDIA and others. The company is a provider of U.S. AI generation drugs services. Translated source brief, not a quotation. Check the original before citing. Sources · 0
BVF Partners, Catalio Capital Management, Cooley, Deep Track Capital, Eli Lilly, Gaingels, Insight Partners, NVIDIA, Perceptive Advisors, RA Capital Management | |||
| Sep 9, 2024 | — · Series A | Catalio Capital Management, Cooley, Eli Lilly, Eli Lilly and Company, Gaingels, Insight Partners, NVIDIA, RA Capital Management | No source link |
Evidence No source brief is attached to this record. Sources · 0
Catalio Capital Management, Cooley, Eli Lilly, Eli Lilly and Company, Gaingels, Insight Partners, NVIDIA, RA Capital Management | |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.